Hernandez Gerardo 4

4 · TransMedics Group, Inc. · Filed Mar 4, 2026

Form 4

Period: 2026-03-02

Chief Financial Officer

Transactions

Sale
Common Stock
[F1]
2026-03-02$139.12/sh−375$52,170→ 14,689 total
Exercise/Conversion
Common Stock
2026-03-04$77.12/sh+1,324$102,107→ 16,013 total
Sale
Common Stock
[F2]
2026-03-04$147.21/sh−1,324$194,906→ 14,689 total
Exercise/Conversion
Common Stock
2026-03-04$69.84/sh+5,912$412,894→ 20,601 total
Sale
Common Stock
[F2]
2026-03-04$147.21/sh−5,912$870,306→ 14,689 total
Exercise/Conversion
Stock Option (Right to Buy)
[F3]
2026-03-04−1,324→ 3,975 total
Exercise: $77.12Exp: 2035-02-24→ Common Stock (1,324 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F4]
2026-03-04−5,912→ 13,010 total
Exercise: $69.84Exp: 2034-12-09→ Common Stock (5,912 underlying)

Footnotes (4)

[F1]Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction pursuant to the terms of the RSU award.
[F2]The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $147.14 to $147.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
[F3]The option vests at a rate of 2.0833% of the total number of shares subject to the option each month following February 24, 2025 until the option is fully vested on February 24, 2029, subject to continued service.
[F4]The option vested as to 25% of the shares underlying the option on December 2, 2025 and will continue to vest as to the remaining shares in equal monthly installments over three years thereafter, subject to continued service.

Signature

By: /s/ Gerardo Hernandez|2026-03-04

Documents

1 file